Neogen vs Zoetis Which Is Stronger?

Neogen and Zoetis are two prominent companies in the animal health industry, each offering a wide range of products and services for livestock and companion animals. Neogen specializes in innovative solutions for food and animal safety, while Zoetis focuses on pharmaceuticals and vaccines. Investors looking to capitalize on the growing demand for animal health products may consider these two stocks for their portfolio. Both companies have experienced steady growth in recent years, making them appealing options for those seeking opportunities in this sector.

Neogen or Zoetis?

When comparing Neogen and Zoetis, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Neogen and Zoetis.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Neogen has a dividend yield of -%, while Zoetis has a dividend yield of 0.97%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Neogen reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Zoetis reports a 5-year dividend growth of 24.37% year and a payout ratio of 31.44%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Neogen P/E ratio at -111.88 and Zoetis's P/E ratio at 33.21. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Neogen P/B ratio is 0.84 while Zoetis's P/B ratio is 15.42.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Neogen has seen a 5-year revenue growth of 0.12%, while Zoetis's is 0.54%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Neogen's ROE at -0.75% and Zoetis's ROE at 47.99%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $12.00 for Neogen and $176.65 for Zoetis. Over the past year, Neogen's prices ranged from $11.46 to $20.89, with a yearly change of 82.29%. Zoetis's prices fluctuated between $144.80 and $200.53, with a yearly change of 38.49%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.